Evaluation of Efficacy and Safety of the triLift™ System
- Conditions
- Skin LaxityWrinkle
- Interventions
- Device: triLift system
- Registration Number
- NCT05773924
- Lead Sponsor
- Lumenis Be Ltd.
- Brief Summary
Single center, single-arm, prospective, open Label with Before \& After Study Design.
- Detailed Description
Single center, single-arm, prospective, open Label with Before \& After Study Design. The control group will be the subjects before the triLift™ treatment protocol and the experimental group will consist of the same subjects after completion of the triLift™ treatment protocol.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 25
- Subject is willing and able to read, understand, and sign the informed consent.
- Healthy male or female aged 35 - 55 years.
- Fitzpatrick skin type 1-6.
- Subject is capable of reading, understanding, and following instructions of the procedure to be applied.
- Subject is able and willing to comply with the treatment. Women in childbearing age who is willing to conduct a pregnancy test prior to each treatment.
- Pregnant, lactating, or plans to become pregnant during the study period or had given birth less than 6 months ago.
- Concurrent participation in any other study.
- Subject has a pacemaker or internal defibrillator, implanted neurostimulators or any other internal electric device or patient who had an implant in the past.
- Subject has metal or other implants in the treatment area (Not including dental fillings, implants and crowns).
- Subject has significant concurrent skin conditions affecting areas to be treated such as sores, bleeding, skin fragility, eczema or psoriasis.
- Subject has burned, blistered, irritated, or sensitive skin due to excessive fresh tanning in areas to be treated or is unlikely to refrain from excessive tanning during the study.
- Subject has used oral isotretinoin (Accutane® or Roaccutan®) within 6 months prior to study.
- Subject has used topical retinoids in the past 1 month.
- History of systemic cancer; premalignant skin lesion or skin concern treatment area.
- Concurrent conditions such as epilepsy, autoimmune, pulmonary or cardiac disorders.
- Poorly controlled endocrine disorders such as diabetes.
- Impaired immune system due to immunosuppressive diseases such as HIV or AIDS, or use of immunosuppressive medications.
- History of collagen disorders, keloid formation or abnormal wound healing.
- Takes or has taken medications, herbal preparations, food supplements or vitamins that might cause fragile skin or impaired skin healing.
- Subject has used oral steroids in the past 6 months.
- Subject has used topical steroids in the past 3 months.
- History of bleeding coagulopathies or use of anticoagulants.
- Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g. ibuprofen containing agents) one week before and after each treatment session prior to treatment.
- Subjects who cannot feel heat to give proper treatment feedback. (nerve damage, etc.)
- Mental disorders that in the opinion of the Investigator would interfere with the ability to comply with the study requirements.
- Subject has any other medical condition that in the opinion of the Investigator warrants exclusion from this study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Trilift system treatment arm triLift system Single arm with Before \& After photos, triLift treatment protocol study design.
- Primary Outcome Measures
Name Time Method The Global Aesthetic Improvement scale (GAI) 4 months The Global Aesthetic Improvement scale (GAI) - Success is defined as an improvement of at least 1 point on the GAI scale assessed by the investigator, at the end of the treatment protocol as compared to baseline.
- Secondary Outcome Measures
Name Time Method 3D images 4 months Measuring facial lifting using 3D imaging and analysis algorithm from Quantificare before and after the treatment protocol
Comfort assessment 3 months Subject assessment of pain and discomfort associated with treatments using a Pain Visual Analogue Scale (VAS), where 0 is "no pain" and 10 is "worst pain possible
Subject level of Satisfaction 4 months Subject satisfaction will be assessed using a 5 level satisfaction questionnaire.
Trial Locations
- Locations (1)
NY Laser Skin Care
🇺🇸New York, New York, United States